Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API


CORRECTION: TIME CHANGE - Lantheus Holdings to Present at November 2020 Investor Conferences


Business Wire | Nov 9, 2020 04:30PM EST

CORRECTION: TIME CHANGE - Lantheus Holdings to Present at November 2020 Investor Conferences

Nov. 09, 2020

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Nov. 09, 2020--Lantheus Holdings, Inc. (the "Company") (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc. and EXINI Diagnostics AB, and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and products, today announced that management will present at two investor conferences in November.

* Credit Suisse 29th Annual Virtual Healthcare Conference Date: Wednesday, November 11, 2020 Time: 9:30am Eastern Time Participants: Mary Anne Heino, President and Chief Executive Officer and Bob Marshall, Chief Financial Officer and Treasurer

* Jefferies Virtual London Healthcare Conference Date: Tuesday, November 17, 2020 Time: 7:20am Eastern Time Participant: Bob Marshall, Chief Financial Officer and Treasurer

To access a live webcast of the presentation, please visit the Investors section of the Company's website at www.lantheus.com. A replay of the webcast will be available on the Company's website for 30 days following the live presentation.

About Lantheus Holdings, Inc.

Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc. and EXINI Diagnostics AB, and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and products. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY(r) Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite(r) (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; AZEDRA(r) for the treatment of certain rare neuroendocrine tumors; and RELISTOR(r) for the treatment of opioid-induced constipation, which is partnered with Bausch Health Companies, Inc. The Company is headquartered in North Billerica, Massachusetts with offices in New York, New Jersey, Puerto Rico, Canada and Sweden. For more information, visit www.lantheus.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201109005984/en/

CONTACT: Mark Kinarney Senior Director, Investor Relations 978-671-8842 ir@lantheus.com

CONTACT: Melissa Downs Director, Corporate Communications 646-975-2533 media@lantheus.com






Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC